Biotech Archives - Page 714 of 733

1 minute read

With All Eyes On Lecanemab Read Out In Alzheimer’s, Uncertainty Overshadows Biogen’s Q2 Beat

July 21, 3:44 PM

Yesterday, Biogen Inc (NASDAQ:BIIB) reported Q2 earnings. Needham writes that while operational performance looked good, uncertainty looms over the company’s growth potential. Lecanemab Phase…

BIIB

1 minute read

HC Wainwright Starts Coverage On This ‘Best-In-Class Agent For Inflammatory Disorders

By Vandana Singh

July 21, 1:01 PM

HC Wainwright initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a Buy rating and a price target of $28, citing a potentially best-in-class…

MLTX

1 minute read

What’s Happening With Addex Therapeutics Shares Today

By Vandana Singh

July 21, 10:51 AM

Addex Therapeutics Ltd (NASDAQ:ADXN) shares are surging after reducing the nominal value of its issued, authorized, and conditional share…

ADXN

1 minute read

Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder

By Vandana Singh

July 21, 10:34 AM

Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating…

TAK

3 minute read

Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners

By Vandana Singh

July 21, 10:14 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ABBV

1 minute read

Recursion Gains European Commission Orphan Drug Status For Rare Tumor Candidate

By Ragothaman Srinivasan

July 21, 10:00 AM

Recursion (NASDAQ: RXRX) received Orphan Drug Designation for REC-4881 from the European Commission towards the potential treatment of familial adenomatous polyposis (FAP).

RXRX

2 minute read

Bionano Genomics Highlights Publication Of Study Using OGM To Investigate Chromosome Instability

By Bill Haddad

July 21, 8:12 AM

Bionano Genomics, Inc. (NASDAQ:BNGO), today announced publication of a study using optical genome mapping (OGM) to investigate numerical and structural changes to two induced pluripotent stem cell (iPSC) lines,

BNGO

1 minute read

X4 Pharma To Stop Further Work On Oncology Programs, Looks For Partner(s)

By Vandana Singh

July 21, 7:58 AM

X4 Pharmaceuticals Inc (NASDAQ:XFOR) updated its strategic priorities that include streamlining resources to focus on advancing its lead candidate, mavorixafor, in…

XFOR

4 minute read

Incannex Receives Ethics Approval To Commence Phase 1 Clinical Trial Of Multi-Use Anti-Inflammatory Drug IHL-675A

By Bill Haddad

July 21, 7:56 AM

Highlights: Bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of IHL-675A on July 20, 2022 The trial will be performed at CMAX Clinical

IXHL

2 minute read

Olema Oncology Receives FDA Fast Track Designation For OP-1250 For Treatment Of ER+ / HER2- Metastatic Breast Cancer

By Bill Haddad

July 21, 7:36 AM

Olema Pharmaceuticals, Inc. ((&ldquo, Olema&rdquo, or &ldquo, Olema Oncology, &rdquo, NASDAQ:OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250, the

OLMA